Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.

Original publication

DOI

10.1016/j.drudis.2013.07.011

Type

Journal article

Journal

Drug Discov Today

Publication Date

12/2013

Volume

18

Pages

1221 - 1227

Keywords

Cooperative Behavior, Drug Design, Drug Discovery, Drug Industry, Humans, Molecular Conformation, Small Molecule Libraries